Aura Biosciences(AURA) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Aura Biosciences Reports Second Quarter 2025 Financial Results and Business Highlights Continued Clinical Program Execution in the Phase 3 CoMpass Trial in Early Choroidal Melanoma and the Phase 1b/2 Trial in Non-Muscle Invasive Bladder Cancer (NMIBC) Strengthened Balance Sheet with $75 Million Equity Financing; Cash Position Expected to Fund Operations into the First Half of 2027 Metastases to the Choroid Metastases to the choroid is an indication with high unmet medical need and no approved t ...